Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue
Collaboration revenue	$ 3,051	$ 3,051
Total revenue	97,666	81,626
Operating expenses
Research and development	73,444	43,496
Selling, general and administrative	156,619	77,971
Total operating expenses	273,427	154,930
Loss from operations	(175,761)	(73,304)
Other income (expense)
Interest income and other, net	8,049	263
Interest expense	0	(1,324)
Change in fair value of warrant liabilities	30,968	(6,952)
Change in fair value of earn-out liability	26,870	(1,869)
Loss on extinguishment of debt, net	0	(4,323)
Total other income (expense)	65,887	(14,205)
Net loss before income tax benefit (provision)	(109,874)	(87,509)
Income tax expense (benefit)	717	(38)
Net loss	(109,157)	(87,547)
Other comprehensive loss
Net unrealized loss on available-for-sale securities	(424)	(68)
Foreign currency translation loss	(17)	(2)
Total other comprehensive loss	(441)	(70)
Comprehensive loss	$ (109,598)	$ (87,617)
Net loss per share, basic (in dollars per share)	$ (0.59)	$ (0.64)
Net loss per share, diluted (in dollars per share)	$ (0.59)	$ (0.64)
Weighted-average shares used in computing net loss per share, basic (in shares)	183,991,643	137,157,283
Weighted-average shares used in computing net loss per share, diluted (in shares)	183,991,643	137,157,283
Assay services revenue
Revenue
Revenue	$ 63,038	$ 68,038
Operating expenses
Cost of revenue	41,419	32,782
Product revenue
Revenue
Revenue	4,243	1,277
Operating expenses
Cost of revenue	1,945	681
Other revenue
Revenue
Revenue	$ 27,334	$ 9,260